Various tumor markers are used in clinical practice to monitor treatment, characterize disease and support cancer diagnosis and treatment. Our Tumor Technical Note presents our most popular tumor marker antibodies: PGI and PGII, PSA, Hemoglobin, CEA, CA 125, CA 19-9 and more, and includes pair recommendations and other essential data to help your reagent validation needs. Technical Note Tumor
Download our ebook here

We have a lot of exciting updates we’d like to share with you.

Here’s a preview:

  • Quality is king – the role of high quality raw materials in IVD success
  • An expert guide on antibody and antigen pairings
  • E-book: Driving the future of cardiovascular diagnostics

I’d like to receive the latest updates:

The diagnosis and monitoring of cancer is a complex process, requiring the application of biomarkers to identify tumors, investigate their origins and monitor their development. Rapid access to the right reagents for these biomarkers is vital in order for you to develop and manufacture high-quality immunoassays that are needed to monitor cancer patients’ health after initial treatment.

Our reagents

The Medix Biochemica Group product portfolio provides a single source of antibodies, antigens, and validation biospecimens for your cancer marker immunoassay development projects meaning you have rapid access to critical raw materials.

Many of these raw materials are already validated and widely used in the IVD test development. We also provide many emerging cancer-associated markers. These include:

Carcinoembryonic antigen (CEA)

Marker to monitor the re-occurrence of a wide range of cancers, including: colorectal cancer, bladder, breast, lung, ovarian, pancreatic, stomach and thyroid.

Discover our CEA products:

Neuron-specific enolase (NSE)

Follow-up marker for neuron-specific enolase-secreting tumors, including: neuroblastoma, small cell lung cancer, medullary thyroid cancer, carcinoid tumors, pancreatic endocrine tumors and melanoma.

Discover our NSE products:

Squamous cell carcinoma antigen (SCC)

An endogenous protease inhibitor that has elevated expression levels in several cancer types.1 Ideal for monitoring: small cell lung cancer, cervical cancer, and head and neck cancers.

Discover our SCC products:


In addition, we supply both monoclonal antibodies and native or recombinant antigens for a host of other markers, including: PSA, CA 15-3, CA 125, CA 19-9, CA 72-4, CA 50, CA 242, CYFRA 21-1, Hemoglobin, AFP and S100B.

Discover all our tumor markers:


Discuss your sample needs with one of our team, contact us today.


1. Suminami, Y., Nagashima, S., Vujanovic, N. et al. Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer 82, 981–989 (2000)

Patient samples suitable for cancer assay validations

We also offer a wide range of biological materials to provide patient samples suitable for cancer assay validations.

Patient samples – Serum:

Patient samples – Plasma:

Healthy control Biospecimens – ideal for use in biological matrices or negative controls:



* Healthy controls can typically be age / gender matched. Contact our team for more information

Find out more about our products

Visit our websites for more information:

Discover our most popular tumor marker reagents in this leaflet:
Tumor marker reagents flyer

To learn more about how we can help you meet your project’s unique needs, contact our team today.